Description of *Bartonella ancashensis* sp. nov., isolated from the blood of two patients with verruga peruana

Kristin E. Mullins,^{1,2} Jun Hang,³ Ju Jiang,² Mariana Leguia,⁴ Matthew R. Kasper,⁴ Palmira Ventosilla,⁵ Ciro Maguiña,⁵ Richard G. Jarman,³ David Blazes¹ and Allen L. Richards^{1,2}

¹Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA

²U.S. Naval Medical Research Center, Silver Spring, MD 20910, USA

³Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA

⁴U.S. Naval Medical Research Unit No. 6, Lima, Peru

⁵Instituto de Medicina Tropical Alexander von Humboldt-Universidad Peruana Cayetano Heredia, Lima, Peru

Three novel isolates of the genus *Bartonella* were recovered from the blood of two patients enrolled in a clinical trial for the treatment of chronic stage *Bartonella bacilliformis* infection (verruga peruana) in Caraz, Ancash, Peru. The isolates were initially characterized by sequencing a fragment of the *gltA* gene, and found to be disparate from *B. bacilliformis*. The isolates were further characterized using phenotypic and genotypic methods, and found to be genetically identical to each other for the genes assessed, but distinct from any known species of the genus *Bartonella*, including the closest relative *B. bacilliformis*. Other characteristics of the isolates, including their morphology, microscopic and biochemical properties, and growth patterns, were consistent with members of the genus *Bartonella*. Based on these results, we conclude that these three isolates are members of a novel species of the genus *Bartonella* for which we propose the name Bartonella *ancashensis* sp. nov. (type strain $20.00^{T} = \text{ATCC BAA-} 2694^{T} = \text{DSM } 29364^{T}$).

The genus *Bartonella* contains more than 30 vector-borne, fastidious, small, Gram-negative bacilli (Birtles *et al.*, 1995; Brenner *et al.*, 1993; Kaiser *et al.*, 2011). Within this genus, three organisms are well-characterized human pathogens (*Bartonella quintana, Bartonella henselae* and *Bartonella bacilliformis*) and others are opportunistic pathogens that cause illness primarily in immune-compromised individuals (Harms & Dehio, 2012; Houpikian & Raoult, 2001; Kaiser *et al.*, 2011; Rolain *et al.*, 2004). The original member of the genus, *B. bacilliformis*, is known to cause Carrión's disease, which is a biphasic illness consisting of an acute phase (also known as Oroya fever) and a chronic

Abbreviations: ITS, intergenic spacer; MLST, multi locus sequence typing; MST, multi spacer typing.

The GenBank/EMBL/DDBJ accession numbers for the *gltA*, *rpoB*, *ftsZ*, *groEL* and *ribC* housekeeping genes, the *rrs* ribosomal gene and the 16S–23S gene ITS of strain 20.00^{T} are KP720638–KP720644, respectively. The GenBank/EMBL/DDBJ accession numbers for the *gltA*, *rpoB*, *ftsZ*, *groEL* and *ribC* housekeeping genes, the *rrs* ribosomal gene and the 16S–23S gene ITS of strain 41.60 are KP7206345–KP720651, respectively.

phase (also known as verruga peruana) (Alexander, 1995; Kosek *et al.*, 2000; Sanchez Clemente *et al.*, 2012). Verruga peruana is characterized by benign yet persistent redpurple, raised skin nodules. Additionally, *B. bacilliformis* infection is seen only in the Andes mountain range of Peru, Ecuador and in Colombia (at 2500–8000 feet above sea level), where it is endemic and likely transmitted by the new world sandfly (*Lutzomyia* species) (Alexander, 1995; Kosek *et al.*, 2000; Sanchez Clemente *et al.*, 2012). Although *Bartonella rochalimae* has been reported to have caused an Oroya-fever-like illness in an American traveller returning from Peru (Eremeeva *et al.*, 2007), *B. bacilliformis* is currently the only agent identified to cause Carrión's disease.

We recently described the isolation of a novel *Bartonella* agent, designated Bartonella *ancashensis* sp. nov., during an antibiotic treatment trial, which was designed to test the efficacy of azithromycin, as compared with standard care (rifampicin), for the treatment of verruga peruana caused by *B. bacilliformis* in Caraz, Ancash, Peru (Blazes *et al.*, 2013). In total, three isolates were obtained from

Correspondence Kristin E. Mullins Email: kristin.e.mullins3.ctr@mail.mil the blood of two patients with verruga peruana who were enrolled in the trial. Two of the isolates came from a three-year-old male: the first (20.00^{T}) was collected at the time of enrollment, and the second (20.60), 60 days post enrollment. The third isolate (41.60) was collected from a ten-year-old male at 60 days post enrollment. We also reported gene sequencing results, multi locus sequence typing (MLST) results, and intergenic spacer (ITS) typing results for *B. ancashensis* sp. nov. strains 20.00^{T} and 20.60. Five housekeeping genes, including gltA (citrate synthase;1341 bp), rpoB (RNA polymerase-beta subunit; 4149 bp), ftsZ (cell division protein; 1776 bp), groEL (60 kDa heat shock-protein; 1644 bp) and ribC (riboflavin synthase; 642 bp), and one ribosomal gene, rrs (16S rRNA gene; 1474 bp), were used for MLST, while the 16S-23S rRNA gene ITS (940 bp) was used for ITS typing (Mullins et al., 2013). Sequencing analysis showed strains 20.00^T and 20.60 to be identical to one another genetically at these loci, vet distinct from all other isolates listed in GenBank. Additionally, the sequencing, MLST and ITS sequencing results showed that the isolates fall within the sequence similarity range for known species of the genus Bartonella. They were most closely related to, yet distinct from, even the most diverse strains of the species B. bacilliformis. The multi-gene sequence divergence and phylogenetic distance analysis clearly indicated that they represent a novel species of the genus Bartonella (Mullins et al., 2013).

Here, we report on the further characterization of *B. ancashensis* sp. nov. by describing additional genotypic, phenotypic, morphological, microscopic, biochemical and growth characteristics of the three strains: 20.00^{T} , 20.60 and 41.60.

To assess the culture characteristics of all three strains, they were cultivated on different solid media at different temperatures and in the presence or absence of increased CO₂. The strains were grown in plates containing either trypticase soy agar (TSA) containing 5 % (v/v) defibrinated sheep blood, chocolate agar (GC agar with haemoglobin and IsoVitaleX), Columbia agar containing 5 % (v/v) defibrinated sheep blood, or deep-fill (extra volume of media to combat drying) heart-brain infusion agar (BHIA) containing 10 % (v/v) defibrinated sheep blood (BD). The cultures were incubated at 26, 30 and 35 °C with or without 5 % CO_2 in a moist atmosphere for at least 20 days. Additionally, strains were tested for their ability to grow in liquid culture (MS10 media) and in Vero and L929 cells cultured in Eagle's minimal essential medium (E-MEM) containing 10 % (v/v) fetal bovine serum at 30 °C with 5 % CO₂ (Lynch et al., 2011).

The strains were subjected to Gram staining (BD) and visualized by light microscopy ($\times 1000$) model B $\times 40$ (Olympus). Cell morphology was visualized by transmission electron microscopy (TEM; 100 CXII; JEOL) with negative staining. Gram staining and TEM were performed on 10 and 28 day cultures passaged one to two times from frozen stocks onto BHIA with 10 % (v/v) defibrinated sheep blood at 30 °C in a moist atmosphere with 5 % (v/v) CO₂.

Biochemical analysis was carried out using the RapID ANA II system (Remel), according to the manufacturer's instructions (Clarridge *et al.*, 1995; Dehio *et al.*, 2001; Sander *et al.*, 1997). Additionally, Oxidase Reagent Droppers (BD) were used to evaluate oxidase activity, while 3 % (v/v) hydrogen peroxide (Acros) was used to evaluate the catalase activity of the three isolates. The biochemical analyses were performed on 10-day-old colonies, which were grown on BHI containing 10 % (v/v) defibrinated sheep blood.

Antibiotic susceptibility was assessed using the Equine species MIC plate (EQUINF1; Trek Diagnostic Systems). Susceptibility testing was carried out according to the manufacturer's instructions for fastidious organisms. In brief, 3–5 colonies were emulsified in 4 ml of MS10 medium and 50 μ l of the suspension was transferred to 11 ml MS10 medium and vortexed. A 100 μ l sample of the solution was added to each well and incubated at 30 °C with 5 % (v/v) CO₂ for up to 18 days.

For additional genotypic characterization, all three strains were subjected to full genome sequencing using a Roche GS FLX Titanium sequencing system and assembly software GSAssembler v2.5.3 (Roche 454 Life Sciences). DNA G+C content of the isolates was determined. Complete sequences of the five housekeeping genes, *gltA*, *rpoB*, *ftsZ*, *groEL*, *ribC* and *rrs* and the 16S–23S ITS, were extracted from the genome sequence of 41.60 for comparison with the respective genes of 20.00^T and 20.60. MLST analysis was employed using concatenated fragments of *rrs*, *rpoB*, *gltA* and *ftsZ* of strain 20.00^T and 30 type strains of species of the genus *Bartonella*.

The results from the genome sequencing of strain 41.60 revealed that *gltA*, *rpoB*, *ftsZ*, *groEL*, *ribC*, *rrs* and the 16S–23S ITS were 100 % identical to their respective counterparts derived from 20.00^{T} and 20.60. Additionally, whole genome sequencing showed the DNA G + C content of these three strains to be 38.4 mol%. This is similar to the DNA G + C content of other known species of the genus *Bartonella* (Bermond *et al.*, 2000,2002). Finally, MLST analysis confirmed *B. ancashensis* sp. nov. (represented by strain 20.00T) to be a novel species of the genus *Bartonella*, most closely related to *B. bacilliformis* (Fig. 1).

All three strains grew on TSA containing 5 % (v/v) defibrinated sheep blood, Columbia agar containing 5 % (v/v) defibrinated sheep blood and on deep-filled BHIA containing 10 % (v/v) defibrinated sheep blood, while none of the strains grew on chocolate agar. All three strains grew optimally at 30 °C with 5 % (v/v) CO₂, with visible colonies observed (for all three isolates) after 10 days. Growth was stunted at 30 °C without CO₂ and at 26 °C, with or without CO₂ (i.e. no individual colonies were visible at 10 days). Finally, no growth was observed at 35 °C with or without 5 % (v/v) CO₂. Cultures remained viable at 30 °C with 5 % (v/v) CO₂ for at least 30 days post-inoculation on BHIA with 10 % (v/v) defibrinated sheep blood. Additionally, all three strains grew in MS10 broth and in Vero and L929 cell culture.



Fig. 1. MLST phylogeny for a 3277 character fragment consisting of concatenated gene fragments *rrs* (1352 characters), *rpoB* (825 characters), *gltA* (312 characters) and *ftsZ* (788 characters) of 30 type strains of species of the genus *Bartonella* with *Brucella melitensis* as the out group. The phylogeny was created with (Tamura *et al.*, 2013) using the neighbour-joining tree method and distances were calculated using the Jukes–Cantor method. Bar, number of base pair substitutions per site.

Colonies passaged four times from frozen isolates were visualized at 10 and 14 days on deep-fill BHIA containing 10 % (v/v) defibrinated sheep blood at 30 °C in a moist atmosphere with 5 % (v/v) CO₂. At 10 days, colonies of 20.00^T were iridescent-grey, opaque, smooth and 1–2 mm in diameter size, while 20.60 appeared as pinpoint colonies. Additionally, the appearance of 41.60 was of a heterogeneous population of iridescent-grey, opaque and smooth colonies, which were 0.8–1 mm in size, or less than 0.5 mm in size at 10 days. At 14 days, 20.00^T colonies were iridescent-grey and opaque, with a depressed centre and 2–3 mm in size. At day 14, colonies of 20.60 were iridescent-grey, translucent and \leq 0.5 mm in size, while 41.60 now exhibited a more homogeneous population of iridescent-grey, opaque and smooth colonies, largely 0.8–1 mm in size.

Gram staining and electron microscopy revealed small Gramstain-negative coccobacilli/bacilli, while TEM revealed 1.27 μ m × 0.54 μ m (20.00^T), 0.99 μ m × 0.64 μ m (20.60) and 1.51 μ m × 0.62 μ m (41.60) bacilli with variable expression of polar flagella (Fig. 2).

All three strains were catalase-, oxidase-, urease- and indole-negative. Additionally, all three strains were negative for the hydrolysis of *p*-nitrophenyl- β -D-disacharide (BLTS), α -L-arabinoside, ONPG, β -D-glucoside, α -D-glucoside, L-fucoside, D-glucosamide and *p*-nitrophenylphosphate. Arylamidase activity was weakly to moderately positive for proline and phenylalanine and positive for leucine, glycine, arginine and serine, but negative for pyrrolidonyl. These results are consistent with those for other members of the genus *Bartonella* (Bermond *et al.*, 2000).

(a)

In addition, the results gave a 000 671 score on the RapID ANA II system, which is identical to the results obtained for many species of the genus *Bartonella*, yet differs from the score obtained for *B. bacilliformis* (000 641) (Clarridge *et al.*, 1995).

Antibiotic susceptibility testing revealed sensitivity to amikacin ($\leq 2 \ \mu g \ ml^{-1}$), azythromycin ($\leq 0.125 \ \mu g \ ml^{-1}$), ceftiofur ($\leq 0.125 \ \mu g \ ml^{-1}$), chloramphenicol ($\leq 2 \ \mu g \ ml^{-1}$), enofloxacin ($\leq 0.125 \ \mu g \ ml^{-1}$), ticarcillin ($\leq 4 \ \mu g ml^{-1}$), ampicillin ($\leq 0.125 \ \mu g \ ml^{-1}$), ticarcillin ($\leq 4 \ \mu g ml^{-1}$), ampicillin ($\leq 0.125 \ \mu g \ ml^{-1}$), clarithromycin ($\leq 0.5 \ \mu g \ ml^{-1}$), gentamicin ($\leq 0.5 \ \mu g \ ml^{-1}$), erythromycin ($\leq 0.125 \ \mu g \ ml^{-1}$), doxycycline ($\leq 1 \ \mu g \ ml^{-1}$), rifampicin ($\leq 1 \ \mu g \ ml^{-1}$) and tetracycline ($\leq 1 \ \mu g \ ml^{-1}$). In addition, strains 20.00^T and 20.60 had an MIC of >2 $\mu g \ ml^{-1}$ for oxacillin +2 % (w/v) NaCl, while 41.60 was sensitive to $\leq 0.125 \ \mu g \ ml^{-1}$ oxacillin +2 % (w/v) NaCl. All three strains produced MICs of >8 $\mu g \ ml^{-1}$ for cefazolin, 1 $\mu g \ ml^{-1}$ for ceftazidime, 0.5 $\mu g \ ml^{-1}$ for penicillin and up to 1 $\mu g \ ml^{-1}$ for imipenem.

In conclusion, the sequencing results, MLST and ITS analysis, along with the phenotypic, morphological, microscopic, biochemical and growth characteristics of the three isolates (strains 20.00^T, 20.60 and 41.60), indicate that they represent a single novel species belonging to the genus *Bartonella*, for which the name Bartonella *ancashensis* sp. nov. is proposed.

Description of Bartonella ancashensis

Bartonella *ancashensis* (an.cash.en'sis. N.L. fem. adj. *ancashensis* pertaining to the Ancash region of Peru).



(b)

Fig. 2. Electron micrograph of isolates 20.00^T (a) and 41.60 (b) showing the variable expression of flagella. Bar, 1 μm.

After a 10 day incubation on BHIA containing 10 % (v/v) defibrinated sheep blood at 30 °C with 5 % (v/v) CO₂, colonies appear round, iridescent-grey, opaque, smooth and 1-2 mm in size. Cells are Gram-stain-negative bacilli, which lack flagella and are 1.27 μ m \times 0.54 μ m. Oxidase, catalase, urease and indole tests are negative. Hydrolysis of *p*-nitrophenyl- β -D-disacharide (BLTS), α -L-arabinoside, ONPG, β -D-glucoside, α -D-glucoside, L-fucoside, D-glucosamide and *p*-nitrophenylphosphate is negative. Arylamidase activity is weakly positive for proline and phenylalanine and positive for leucine, glycine, arginine and serine, but negative for pyrrolidonyl. This gives a 000 671 code using the RapID ANA II system. This species can be distinguished from other species of the genus Bartonella by rrs, ftsZ, gltA, groEL, ribC and rpoB gene and 16S-23S ITS region sequences.

The type strain is $20-00^{T}$ (=ATCC BAA-2694^T=DSM 29364^T), the first isolate collected and isolated prior to antibiotic treatment from a three-year-old male living in a rural setting outside of the town of Caraz, in the high-lands of the Ancash region of Peru. The type strain has a DNA G+C content of 38.4 mol%.

Disclaimer

M. L., R. G. J., D. B. and A. L. R. are military service members or employees of the US Government and this work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that 'Copyright protection under this title is not available for any work of the United States Government'. Title 17 U.S.C. §101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties. The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Army, the Department of the Navy, the Department of Defense, or the US Government.

References

Alexander, B. (1995). A review of bartonellosis in Ecuador and Colombia. *Am J Trop Med Hyg* 52, 354–359.

Bermond, D., Heller, R., Barrat, F., Delacour, G., Dehio, C., Alliot, A., Monteil, H., Chomel, B., Boulouis, H. J. & Piémont, Y. (2000). *Bartonella birtlesii* sp. nov., isolated from small mammals (*Apodemus* spp.). *Int J Syst Evol Microbiol* **50**, 1973–1979.

Bermond, D., Boulouis, H.-J., Heller, R., Van Laere, G., Monteil, H., Chomel, B. B., Sander, A., Dehio, C. & Piémont, Y. (2002). *Bartonella bovis* Bermond *et al.* sp. nov. and *Bartonella capreoli* sp. nov., isolated from European ruminants. *Int J Syst Evol Microbiol* **52**, 383–390.

Birtles, R. J., Harrison, T. G., Saunders, N. A. & Molyneux, D. H. (1995). Proposals to unify the genera *Grahamella* and *Bartonella*, with descriptions of *Bartonella talpae* comb. nov., *Bartonella peromysci* comb. nov., and three new species, *Bartonella grahamii*

sp. nov., Bartonella taylorii sp. nov., and Bartonella doshiae sp. nov. Int J Syst Bacteriol 45, 1–8.

Blazes, D. L., Mullins, K., Smoak, B. L., Jiang, J., Canal, E., Solorzano, N., Hall, E., Meza, R., Maguina, C. & other authors (2013). Novel *Bartonella* agent as cause of verruga peruana. *Emerg Infect Dis* 19, 1111–1114.

Brenner, D. J., O'Connor, S. P., Winkler, H. H. & Steigerwalt, A. G. (1993). Proposals to unify the genera *Bartonella* and *Rochalimaea*, with descriptions of *Bartonella quintana* comb. nov., *Bartonella vinsonii* comb. nov., *Bartonella henselae* comb. nov., and *Bartonella elizabethae* comb. nov., and to remove the family *Bartonellaceae* from the order *Rickettsiales*. Int J Syst Bacteriol **43**, 777–786.

Clarridge, J. E. III, Raich, T. J., Pirwani, D., Simon, B., Tsai, L., Rodriguez-Barradas, M. C., Regnery, R., Zollo, A., Jones, D. C. & Rambo, C. (1995). Strategy to detect and identify *Bartonella* species in routine clinical laboratory yields *Bartonella henselae* from human immunodeficiency virus-positive patient and unique *Bartonella* strain from his cat. J Clin Microbiol 33, 2107–2113.

Dehio, C., Lanz, C., Pohl, R., Behrens, P., Bermond, D., Piémont, Y., Pelz, K. & Sander, A. (2001). *Bartonella schoenbuchii* sp. nov., isolated from the blood of wild roe deer. *Int J Syst Evol Microbiol* 51, 1557–1565.

Eremeeva, M. E., Gerns, H. L., Lydy, S. L., Goo, J. S., Ryan, E. T., Mathew, S. S., Ferraro, M. J., Holden, J. M., Nicholson, W. L. & other authors (2007). Bacteremia, fever, and splenomegaly caused by a newly recognized *Bartonella* species. *N Engl J Med* **356**, 2381–2387.

Harms, A. & Dehio, C. (2012). Intruders below the radar: molecular pathogenesis of *Bartonella* spp. *Clin Microbiol Rev* 25, 42–78.

Houpikian, P. & Raoult, D. (2001). 16S/23S rRNA intergenic spacer regions for phylogenetic analysis, identification, and subtyping of *Bartonella* species. *J Clin Microbiol* **39**, 2768–2778.

Kaiser, P. O., Riess, T., O'Rourke, F., Linke, D. & Kempf, V. A. J. (2011). *Bartonella* spp.: throwing light on uncommon human infections. *Int J Med Microbiol* 301, 7–15.

Kosek, M., Lavarello, R., Gilman, R. H., Delgado, J., Maguiña, C., Verástegui, M., Lescano, A. G., Mallqui, V., Kosek, J. C. & other authors (2000). Natural history of infection with *Bartonella bacilliformis* in a nonendemic population. J Infect Dis 182, 865–872.

Lynch, T., Iverson, J. & Kosoy, M. (2011). Combining culture techniques for *Bartonella*: the best of both worlds. *J Clin Microbiol* **49**, 1363–1368.

Mullins, K. E., Hang, J., Jiang, J., Leguia, M., Kasper, M. R., Maguiña, C., Jarman, R. G., Blazes, D. L. & Richards, A. L. (2013). Molecular typing of "*Candidatus* Bartonella ancashi," a new human pathogen causing verruga peruana. *J Clin Microbiol* 51, 3865–3868.

Rolain, J. M., Brouqui, P., Koehler, J. E., Maguina, C., Dolan, M. J. & Raoult, D. (2004). Recommendations for treatment of human infections caused by *Bartonella* species. *Antimicrob Agents Chemother* 48, 1921–1933.

Sanchez Clemente, N., Ugarte-Gil, C. A., Solórzano, N., Maguiña, C., Pachas, P., Blazes, D., Bailey, R., Mabey, D. & Moore, D. (2012). Bartonella bacilliformis: a systematic review of the literature to guide the research agenda for elimination. *PLoS Negl Trop Dis* 6, e1819.

Sander, A., Bühler, C., Pelz, K., von Cramm, E. & Bredt, W. (1997). Detection and identification of two *Bartonella henselae* variants in domestic cats in Germany. *J Clin Microbiol* 35, 584–587.

Tamura, K., Stecher, G., Peterson, D., Filipski, A. & Kumar, S. (2013). MEGA6: Molecular evolutionary genetics analysis version 6.0. *Molecular Biology and Evolution* **30**, 2725–2729.